Press Releases
Osivax Announces First Participant Vaccinated in Phase 2a Clinical Booster Trial of Influenza Vaccine Candidate OVX836 Phase 2a study to evaluate safety and …
Osivax and KM Biologics Enter Exclusive License Option Agreement for Broad-Spectrum “Universal” Influenza Vaccine in Japan KM Biologics, a Meiji Group company, …
Osivax completes Enrollment for Phase 1 Trial with Broad-Spectrum Sarbecovirus Vaccine Candidate, OVX033 48 healthy volunteers enrolled in first-in-human trial Topline …
Osivax Announces Vaccination of Last Patient in Phase 2a Clinical Trial Evaluating OVX836 Combined with QIVs 478 participants were enrolled across Australia …
Osivax Announces Vaccination of First Participant in First-in-Human Trial Evaluating Sarbecovirus Vaccine Candidate OVX033 Phase 1 study to evaluate safety and immunogenicity …
Osivax Appoints Dr. Nicola Groth as Chief Medical Officer Lyon, France – January 25, 2024 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum …
Osivax Receives Over USD 1.5M Grant from NIAID to Advance Development of Broad-Spectrum Influenza Vaccine Candidate, OVX836 Grant to support preclinical evaluation of …
Osivax Announces Publication in The Lancet Infectious Diseases of Phase 2a Data for Broad-Spectrum Influenza Vaccine Candidate, OVX836 OVX836 demonstrated positive safety …
Osivax Publishes Preclinical Data for Sarbecovirus Vaccine Candidate, OVX033in Frontiers in Immunology Evidence of cross-protection against multiple SARS-CoV-2 variants of concern observed …
Osivax Announces Vaccination of First Participant in Phase 2a Clinical Trial Evaluating OVX836 Combined with QIVs Australia-based Phase 2a clinical study to …
Osivax Awarded Grant from a Leading Non-Governmental Organization for OVX836, its Broad-Spectrum Influenza Vaccine A Bill & Melinda Gates Foundation grant will …
Osivax Appoints Dr. Chris Martin, Renowned Biotech Entrepreneur, to its Board of Directors Company honors Dr. Michael Watson for his significant impact …
Osivax Announces Last Patient Last Visit in Two Phase 2a Clinical Trials with Broad-Spectrum Influenza Vaccine Candidate OVX836 Lyon, France – December 21, …
Osivax Appoints Vincent Bille as Chief Manufacturing Officer and Announces Manufacturing Progress for OVX836 Dr. Bille will oversee manufacturing scale-up for broad-spectrum …
Osivax Announces Clinical and Preclinical Vaccine Data Presentations at Upcoming Global Influenza Conferences Influenza vaccine candidate OVX836 safety profile and efficacy signals …
Osivax Secures EUR 10M Grant from Bpifrance to Support Clinical Development of OVX836, a Broad-Spectrum Influenza Vaccine Lyon, France – June 23, 2022 – Osivax, …
Osivax Provides Clinical Development Update on Lead Influenza Vaccine Candidate OVX836 Excellent safety continues to be observed in ongoing Phase 2a dose …
Osivax Enters Research Collaboration with the NIAID for the Evaluation of Combination Approach to Broad-Spectrum Influenza Vaccines Lyon, France – May 17, 2022 – …
Data also discussed in context of OVX836 clinical development update presentation at 2022 World Vaccine Congress Lyon, France – April 21, 2022 – …
Company also announces upcoming presentation of clinical data for its pan-influenza vaccine candidate at World Vaccine Congress Lyon, France – April 14, …
Osivax Announces Promising Phase 2a Results with Universal Influenza Vaccine Candidate, OVX836, and Initiation of Additional Phase 2a Dose Optimization Study Phase …
Osivax Announces Publication of Phase 1 Data on its Broad-Spectrum Influenza Vaccine Candidate OVX836 in the Journal of Infectious Diseases Encouraging safety …
Rip Ballou’s appointment will strengthen OSIVAX’s ambition to develop a pipeline of disruptive vaccines against infectious diseases. Lyon, France – September 22, …
Osivax announces Last Subject Last Visit completed in Phase 2a Clinical Trial of OVX836 Universal Influenza Vaccine Candidate — Full immunogenicity and …
OSIVAX Announces Completion of Enrolment in its Phase 2a Clinical Trial of OVX836 Universal Influenza Vaccine Candidate — Top line results expected …
Osivax Announces First Volunteers Enrolled in Phase 2a clinical trial of OVX836 Universal Influenza Vaccine Candidate — Phase 2a clinical trial on 300 healthy …
Osivax Enters Agreement with U.S. National Institutes of Health to Test Universal Flu Vaccine Candidate Lyon, France – December 5, 2019 – Osivax announced …
Osivax Extends Executive Team to Strengthen Corporate Expansion and Accelerate the Development of Universal Flu Vaccine Candidate— Linda Lebon joins as Chief …
Osivax Announces Last Participant Last Visit in its Phase 1 Clinical Trial of OVX836 Universal Influenza Vaccine Candidate– Full safety and immunogenicity …
Osivax Secures EUR 8 Million of Financing through a Series A Round to Develop Novel Universal Flu Vaccines and Expand oligoDOM® Technology …
Paul Willems’ appointment will strengthen Osivax’s capacities to design and implement an ambitious and impactful clinical development plan for its vaccines pipeline …
Osivax announces that the Belgian health authority approved the initiation of a first-in-human clinical trial evaluating the safety and immunogenicity of OVX836 …
As DKFZ’s HPV vaccine candidate based on Osivax’s technology platform (OVX313) reports promising pre-clinical results, a second license agreement was signed Lyon, …
Prof. Almond’s appointment will strengthen Osivax’s capacities to drive, position and prioritize pipeline development and especially OVX836, a broad-spectrum influenza vaccine Lyon, …
This recruitment brings strategic capabilities to drive the development of Osivax’s lead candidate, a breakthrough influenza vaccine Lyon, France – January 24th, …